Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication

Thyroid

Volumn 17, Issue 11, 2007, Pages 1103-1107

  Smith, Jessica ^a,b   Brown, Rosalind S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; THYROXINE BINDING GLOBULIN;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SCHOOL CHILD; SHORT STATURE; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ANTITHYROID AGENTS; AUTOANTIBODIES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GRAVES DISEASE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, THYROTROPIN; RETROSPECTIVE STUDIES;

EID: 36749035307     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0072     Document Type: Article

References (23)

1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM 1998 The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 19:673-716.
2. Gorton C, Sadeghi-Nejad A, Senior B 1987 Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child 141:1084-1086.
3. Collen RJ, Landaw EM, Kaplan SA, Lippe BM 1980 Remission rates of children and adolescents with thyrotoxicosis treated with antithyroid drugs. Pediatrics 65:550-556.
4. Rivkees SA, Sklar C, Freemark M 1998 Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 83:3767-3776.
5. Fenzi G, Hashizume K, Roudebush CP, DeGroot LJ 1979 Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J Clin Endocrinol Metab 48:572-576.
6. Teng CS, Yeung RT 1980 Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 50:144-147.
7. Bliddal H, Kirkegaard C, Siersbaek-Nielsen K, Friis T 1981 Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. Acta Endocrinol (Copenh) 98:364-369.
8. Zurakowski D, Di Canzio J, Majzoub JA 1999 Pediatric reference intervals for serum thyroxine, triiodothyronine, thyrotropin, and free thyroxine. Clin Chem 45:1087-1091.
9. Davies TF, Roti E, Braverman LE, DeGroot LJ 1998 Thyroid controversy - stimulating antibodies. J Clin Endocrinol Metab 83:3777-3785.
10. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J 2004 Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 36:92-96.
11. Feldt-Rasmussen U, Schleusener H, Carayon P 1994 Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78:98-102.
12. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE 2005 Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res 37:745-750.
13. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J 2004 A new assay for thyrotropin receptor autoantibodies. Thyroid 14:830-835.
14. Botero D, Brown RS 1998 Bioassay of thyrotropin receptor antibodies with Chinese hamster ovary cells transfected with recombinant human thyrotropin receptor: clinical utility in children and adolescents with Graves disease. J Pediatr 132:612-618.
15. Foley TP Jr, White C, New A 1987 Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations. J Pediatr 110:378-386.
16. Kamijo K, Ishikawa K, Tanaka M 2005 Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J 52:525-529.
17. Ikenoue H, Okamura K, Sato K, Kuroda T, Yoshinari M, Tokuyama T, Nakagawa M, Fujishima M 1991 Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices. Acta Endocrinol (Copenh) 125:643-650.
18. van Ouwerkerk BM, Krenning EP, Docter R, Bos G, van Oudenaren A, Benner R, Hennemann G 1987 Cellular and humoral immunity in patients with hyperthyroid Graves' disease before, during and after antithyroid drug treatment. Clin Endocrinol (Oxf ) 26:385-394.
19. Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat-Stefanutti A, Orgiazzi J, Allannic H 1984 Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease? Clin Endocrinol (Oxf ) 21:247-255.
20. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P 1998 The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8:119-124.
21. Kim TY, Park YJ, Park do J, Chung HK, Kim WB, Kohn LD, Cho BY 2003 Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs. J Clin Endocrinol Metab 88:117-124.
22. Wenzel KW, Lente JR 1984 Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab 58:62-69.
23. Cooper DS 2003 Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 88:3474-3481.